Senseonics (NYSE:SENS) Sets New 52-Week High - Time to Buy?

Senseonics Holdings, Inc. (NYSE:SENS - Get Free Report) shares hit a new 52-week high during trading on Wednesday . The company traded as high as $1.20 and last traded at $1.19, with a volume of 3529592 shares trading hands. The stock had previously closed at $1.10.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on SENS. HC Wainwright reaffirmed a "buy" rating and set a $2.00 price objective on shares of Senseonics in a research report on Friday, November 15th. StockNews.com initiated coverage on shares of Senseonics in a research report on Thursday, December 26th. They issued a "sell" rating for the company.

Senseonics Price Performance

The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. The stock has a market cap of $672.72 million, a price-to-earnings ratio of -8.69 and a beta of 0.69. The company's 50-day moving average is $0.75 and its 200-day moving average is $0.49.

Insider Buying and Selling

In other news, CFO Frederick T. Sullivan acquired 124,933 shares of the company's stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $0.38 per share, with a total value of $47,474.54. Following the completion of the acquisition, the chief financial officer now owns 2,478,844 shares in the company, valued at approximately $941,960.72. This represents a 5.31 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Timothy T. Goodnow acquired 315,000 shares of the company's stock in a transaction dated Tuesday, December 10th. The shares were purchased at an average cost of $0.31 per share, with a total value of $97,650.00. Following the acquisition, the chief executive officer now owns 11,310,355 shares of the company's stock, valued at approximately $3,506,210.05. This represents a 2.86 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company's stock.

Remove Ads

Institutional Trading of Senseonics

Several hedge funds have recently modified their holdings of the stock. First Light Asset Management LLC bought a new stake in shares of Senseonics during the fourth quarter valued at approximately $3,366,000. Geode Capital Management LLC grew its stake in shares of Senseonics by 9.7% during the fourth quarter. Geode Capital Management LLC now owns 6,405,100 shares of the company's stock valued at $3,354,000 after purchasing an additional 566,704 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Senseonics by 6,694.1% during the fourth quarter. Jane Street Group LLC now owns 6,118,786 shares of the company's stock valued at $3,203,000 after purchasing an additional 6,028,726 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Senseonics by 9.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,339,698 shares of the company's stock valued at $1,748,000 after purchasing an additional 274,842 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in shares of Senseonics during the fourth quarter valued at approximately $720,000. 12.36% of the stock is owned by institutional investors.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.